Alemtuzumab for multiple sclerosis: Long term follow-up in a multi-centre cohort

Willis, Mark ORCID: https://orcid.org/0000-0003-3024-6063, Harding, Katharine, Pickersgill, T., Wardle, Mark, Pearson, O., Scolding, N., Smee, J. and Robertson, Neil ORCID: https://orcid.org/0000-0002-5409-4909 2016. Alemtuzumab for multiple sclerosis: Long term follow-up in a multi-centre cohort. Multiple Sclerosis Journal 22 (9) , pp. 1215-1223. 10.1177/1352458515614092

Preview

PDF - Accepted Post-Print Version Download (386kB) | Preview

Abstract

Background: Alemtuzumab has recently been approved for treatment of relapsing MS, but concerns remain about its use since long-term studies of adverse events remain limited. Furthermore, a clear understanding of its application and durability of effect in clinical practice has yet to evolve. Objectives: To investigate long-term efficacy and safety outcomes in a multicentre cohort of patients treated with alemtuzumab. Methods: Patients treated from 2000 and followed-up at three regional centres were identified. Baseline and prospective data were obtained and validated by clinical record review. Results: One hundred patients were identified with a mean follow-up of 6.1 years (range 1–13). Forty patients were retreated with at least one further treatment cycle. Annualized relapse rates fell from 2.1 to 0.2 (p<0.0001) post-treatment and were sustained for up to eight years of follow-up. Mean change in EDSS score was +0.14. Forty-seven patients developed secondary autoimmunity. Conclusion: Observed reduction in relapse rates reflected those reported in clinical trials, but we were unable to corroborate previous observations of disability reversal. 40% of patients required additional treatment cycles. Autoimmune adverse events were common, occurring at a higher rate than previously reported, but were largely predictable, and could be managed effectively within a rigorous monitoring regime.

Item Type:	Article
Date Type:	Publication
Status:	Published
Schools:	Medicine MRC Centre for Neuropsychiatric Genetics and Genomics (CNGG)
Subjects:	R Medicine > R Medicine (General) R Medicine > RC Internal medicine > RC0321 Neuroscience. Biological psychiatry. Neuropsychiatry
Publisher:	Sage
ISSN:	1352-4585
Date of First Compliant Deposit:	8 March 2018
Date of Acceptance:	1 October 2015
Last Modified:	25 Nov 2024 10:30
URI:	https://orca.cardiff.ac.uk/id/eprint/87147

Citation Data

Cited 76 times in Scopus. View in Scopus. Powered By Scopus® Data

Actions (repository staff only)

Edit Item